Earnings Call Insights: EDAP TMS S.A. (EDAP) Q1 2026
MANAGEMENT VIEW
*
“As announced this morning, we delivered a strong first quarter. We reported record first quarter total revenue for the company of $17.8 million, led by record first quarter Focal One Robotic HIFU revenue of $11.6 million,” said (CEO & Director Ryan Rhodes), adding that EDAP “recorded 11 capital sales and 10 total net placements” and is seeing multi-site expansion as “11 U.S. hospital and health networks have now invested in and launched 2 or more Focal One robotic HIFU programs.”
*
Rhodes highlighted reimbursement-driven and indication-driven international momentum, including France’s first cash sale after “the French National Health System's decision to provide universal coverage for the Focal One HIFU procedure,” and said demand in Q1 “marked the first time our Focal One capital sales were driven by demand across 2 clinical indications, prostate cancer and deep infiltrating endometriosis.”
*
“Total company-wide revenue for the first quarter was $17.8 million,” said (Chief Financial Officer Ken Mobeck), and attributed mix-driven profitability improvement to “the strategic shift to our higher-margin HIFU business segment.”
OUTLOOK
*
“We are reiterating our full year 2026 guidance,” said (CFO Mobeck). “We continue to expect core HIFU revenue in the range of $50 million to $54 million, representing 34% to 45% growth over 2025 and combined noncore revenue in the range of $22 million to $26 million.”
*
Compared with the prior quarter call, EDAP’s guidance language stayed consistent (reiterated ranges), while management added a new near-term balance-sheet datapoint: “Subsequent to the end of the first quarter, on April 20, we received the second tranche from the European Investment Bank credit facility totaling approximately $14 million,” according to (CFO Mobeck).
*
EDAP did not provide total company revenue or EPS guidance on the call; guidance was framed around core HIFU revenue and combined noncore revenue.
FINANCIAL RESULTS
*
Q1 revenue was $17.8 million vs. $16.6 million (analysts’ revenue estimate). Net loss was (-$0.24) per share vs. (-$0.22) (analysts’ EPS estimate).
*
“Total HIFU revenue for the first quarter was $11.6 million as compared to $6.5 million for the first quarter of 2025,” said (CFO Mobeck), while noting noncore headwinds: “noncore distribution and ESWL businesses… declined by 20% in Q1 2026 versus Q1 2025.”
*
Profitability and spending moved with growth investments. “Gross margin was 45.7% in the first quarter compared to 42% for the first quarter of 2025,” said (CFO Mobeck), while “operating expenses were $15.5 million for the first quarter compared to $12.3 million for the same period in 2025,” and “operating loss… was $7.4 million.”
*
Balance sheet and cash usage were flagged alongside tariff costs. “Cash and cash equivalents at the end of the first quarter were $15 million compared to $20.5 million at the end of Q4 2025,” said (CFO Mobeck), and “the tariff impact on the first quarter P&L and balance sheet was approximately $400,000.”
Q&A
*
Michael Sarcone, Jefferies: asked what drove “U.S. HIFU procedure growth, 53%” and how sustainable it is; (CEO Rhodes) said growth reflected program maturation: “We've expanded training to additional doctors,” and “we sell and build a program. So we feel very confident that we'll continue to grow our procedures.”
*
Sarcone, Jefferies: asked about surgeons per account; (CEO Rhodes) said EDAP has moved from “that 1.5 number of trained doctors to nearly 2 per site, 2 or more,” adding, “we have some sites where we have as many as 6 urologists trained.”
*
Sarcone, Jefferies: asked about endometriosis financial contribution and U.S. progress; (CEO Rhodes) said revenue modeling was early-stage—“it may be too early to say in our models”—and on the U.S. pathway added, “we're still waiting for published data… We're expecting that data to be published likely sometime this year… [to] play directly back into the conversations that we'll have with the FDA.”
*
Jason Bednar, Piper Sandler: asked about the U.S. runway vs. ex-U.S. emphasis; (CEO Rhodes) said EDAP is “really early in this adoption life cycle” in the U.S., and cited leverage abroad from legacy channels; (CFO Mobeck) added, “it will still be predominantly in the U.S. when it comes to unit sales,” and “we sell direct in the U.S. so we can demand a higher ASP.”
*
Bednar, Piper Sandler: asked about AUA presence and Investor Day content; (CEO Rhodes) described planned activities and said Investor Day would include “some updates on our financial models” and “a technology element, something we haven't discussed or shown before.”
SENTIMENT ANALYSIS
*
Analysts’ sentiment was slightly positive and growth-oriented, emphasizing utilization durability, U.S. runway, and timing/monetization of endometriosis, with questions framed around “how sustainable is that level of growth” (Sarcone, Jefferies) and market mix (Bednar, Piper Sandler).
*
Management’s sentiment was positive in prepared remarks and remained confident in Q&A, repeatedly linking growth to program buildout and adoption; (CEO Rhodes) said, “we feel very confident that we'll continue to grow our procedures,” and called the business “really at an inflection point.”
*
Versus the prior quarter, the tone stayed confident and execution-focused, but Q1 placed more emphasis on multi-indication demand (endometriosis and BPH) and on near-term milestones (AUA, Investor Day) rather than Q4’s heavier focus on regulatory/reimbursement updates.
QUARTER-OVER-QUARTER COMPARISON
*
Compared with Q4 2025, Q1 2026 introduced a reporting change: (CEO Rhodes) said, “effective January 1 of this year, EDAP becomes a U.S. domestic issuer… we will report all financial results in U.S. dollars.”
*
Utilization commentary strengthened: Q1 cited “U.S. procedure volumes increased 53% year-over-year” (Rhodes) versus Q4’s discussion of “28%” year-over-year procedure growth.
*
Strategic emphasis broadened from prostate cancer adoption and next-generation platform progress in Q4 (including FDA clearance for a “latest evolution” of Focal One) to Q1’s multi-indication commercial pull-through, with Rhodes highlighting that systems were being purchased for “both prostate cancer and endometriosis.”
RISKS AND CONCERNS
*
Tariffs remained a stated headwind, with (CFO Mobeck) quantifying Q1 impact: “approximately $400,000.”
*
Cash usage and liquidity were in focus as EDAP invested for growth; (CFO Mobeck) said the quarter-end cash decline was “driven primarily by cash used in operating activities to support our strategic investments,” and pointed to the “approximately $14 million” EIB tranche received after quarter end.
*
Clinical and regulatory timing risk was implicit in endometriosis U.S. plans; (CEO Rhodes) said the company is “still waiting for published data” and that publication “will be very important… to revisit our strategy with the FDA.”
FINAL TAKEAWAY
Management characterized Q1 as a record quarter led by Focal One Robotic HIFU, tied to higher system activity and accelerating U.S. utilization, while reiterating 2026 core HIFU revenue guidance of $50 million to $54 million. Leadership emphasized multi-site expansion in U.S. health systems, growing international traction supported by reimbursement (including France) and early multi-indication purchasing behavior (prostate cancer and endometriosis). In Q&A, management maintained a confident stance on sustained procedure growth via program buildout and physician training, while framing U.S. endometriosis progress around the timing of upcoming published trial data and subsequent FDA strategy discussions.
Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/edap/earnings/transcripts]
MORE ON EDAP TMS S.A.
* EDAP TMS S.A. (EDAP) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4900844-edap-tms-s-a-edap-q1-2026-earnings-call-transcript]
* EDAP TMS S.A. (EDAP) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4885752-edap-tms-s-a-edap-q4-2025-earnings-call-transcript]
* EDAP TMS S.A. GAAP EPS of -$0.24 misses by $0.01, revenue of $17.81M beats by $1.21M [https://seekingalpha.com/news/4588367-edap-tms-s-a-gaap-eps-of-0_24-misses-by-0_01-revenue-of-17_81m-beats-by-1_21m]
* EDAP TMS S.A. Q1 2026 Earnings Preview [https://seekingalpha.com/news/4587038-edap-tms-s-a-q1-2026-earnings-preview]
* Seeking Alpha’s Quant Rating on EDAP TMS S.A. [https://seekingalpha.com/symbol/EDAP/ratings/quant-ratings]
文章加载中…